ArticleOncotarget2016

FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.

Kah Keng Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.